ALMS logo

ALMS
Alumis Inc.

1,090
Mkt Cap
$3.09B
Volume
4.03M
52W High
$30.60
52W Low
$2.76
PE Ratio
-8.35
ALMS Fundamentals
Price
$25.06
Prev Close
$25.38
Open
$24.84
50D MA
$26.18
Beta
0.86
Avg. Volume
1.31M
EPS (Annual)
-$2.86
P/B
8.71
Rev/Employee
$107,366.07
$558.22
Loading...
Loading...
News
all
press releases
Alumis (NASDAQ:ALMS) Price Target Raised to $38.00
Morgan Stanley lifted their price target on Alumis from $33.00 to $38.00 and gave the stock an "overweight" rating in a report on Friday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Alumis (NASDAQ:ALMS) Given New $38.00 Price Target at Chardan Capital
Chardan Capital boosted their price target on Alumis from $37.00 to $38.00 and gave the stock a "buy" rating in a research report on Friday...
MarketBeat·2d ago
News Placeholder
Alumis (NASDAQ:ALMS) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS
Alumis (NASDAQ:ALMS - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.04). The company had revenue of $1.93 million for the quarter, compared to analyst...
MarketBeat·2d ago
News Placeholder
Alumis (NASDAQ:ALMS) Trading Down 3.5% - Here's What Happened
Alumis (NASDAQ:ALMS) Stock Price Down 3.5% - Here's Why...
MarketBeat·5d ago
News Placeholder
Alumis Inc. (NASDAQ:ALMS) Sees Significant Drop in Short Interest
Alumis Inc. (NASDAQ:ALMS - Get Free Report) was the recipient of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 7,953,241...
MarketBeat·5d ago
News Placeholder
Alumis (NASDAQ:ALMS) Stock Price Down 6.7% - Should You Sell?
Alumis (NASDAQ:ALMS) Shares Down 6.7% - Here's Why...
MarketBeat·10d ago
News Placeholder
Alumis (ALMS) to Release Earnings on Wednesday
Alumis (NASDAQ:ALMS) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 18. (View Earnings Report at...
MarketBeat·11d ago
News Placeholder
Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead
Alumis (NASDAQ:ALMS) executives highlighted recent clinical progress for the company's TYK2 inhibitor programs and previewed multiple upcoming catalysts during remarks at the Leerink Partners Global...
MarketBeat·12d ago
News Placeholder
Alumis Inc. (NASDAQ:ALMS) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Alumis Inc. (NASDAQ:ALMS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twelve brokerages that are currently covering the company, Marketbeat Ratings...
MarketBeat·21d ago
News Placeholder
Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference
Executives from Alumis (NASDAQ:ALMS) outlined upcoming regulatory milestones and provided additional context around recently announced Phase 3 psoriasis results for envudeucitinib during a fireside...
MarketBeat·23d ago
<
1
2
...
>

Latest ALMS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.